The Future of Breast Cancer Treatment is Now!

Print icon

Clinical trials are the means by which doctors and researchers work toward providing newer, better and more innovative health care treatments. This is especially true as the health care community works toward treating cancer. As the charter member of the Memorial Sloan Kettering Cancer Alliance, the Hartford HealthCare Cancer Institute is giving patients access to hundreds of clinical trials. Dr. Patricia DeFusco is the newly-appointed medical director of the Hartford HealthCare Cancer Institute Breast Program

Q: What is the importance of cancer clinical trials? 

A: Clinical trials are the means by which we learn about new therapies, and also learn about the application of very novel therapies to very specific subsets of patients.

Q: What’s new in clinical research?

A: One of the exciting trials we’re involved with Memorial Sloan Kettering is called the Impact Trial. This is the trial where we’re sending off tumor specimens in patients with newly-diagnosed metastatic cancer. Those tumor specimens are analyzed for a number of different pathways. If there is an abnormality found in one of those pathways, it may help to make the patient eligible for a specific clinical trial looking at a drug that might alter that pathway.

Q: Who is the best candidate for something like this?

A: At Hartford HealthCare, we’re doing this quite a bit in the breast program by looking at women with newly-diagnosed metastatic breast cancer. We know that there are differences in the pathways between the initial diagnosis and the presence of metastatic disease. Trying to exploit those differences to find better therapies is what we’re trying to find.

Learn more about locally-available cancer clinical trials here from the Hartford HealthCare Cancer Institute and the Memorial Sloan Kettering Cancer Institute. 


What's New

Ribbon Cutting

New Cancer Institute Opens in Manchester

It’s a new day at Hartford HealthCare that brings with it the grand opening of a state-of-the-art cancer institute on Tolland Turnpike in Manchester and a new CEO at the helm of Hartford HealthCare. Here’s CEO Jeff Flaks: Q. Explain how the launch of this new cancer institute which you...

Ovarian Cancer

Why Ovarian Cancer is Difficult to Diagnose

By Dr. Jonathan A. Cosin Director of Gynecologic Oncology The Hospital of Central Connecticut September is ovarian cancer awareness month, so it’s a good time to learn more about one of the more difficult cancers to diagnose. While ovarian cancer may not be one of the most common cancers among...

Thyroid Nodule

What’s a Thyroid Nodule? And is It Cancerous?

Hospital of Central Connecticut endocrine surgeon Dr. Carrie Carsello, the only Hartford HealthCare surgeon who is fellowship trained in endocrine surgery, says most people diagnosed with a thyroid nodule find it a little scary. “But,” she says, “the vast majority of thyroid nodules are benign, up to 95 percent. Sometimes, though,...

New Doctors

Cancer Institute Adds Four Medical Oncologists

The Hartford HealthCare Cancer Institute announced the appointment of the following four new providers: Dr. Sara Dost, a medical oncologist and hematologist whose clinical interests are breast oncology and supportive care of cancer patients, begins in August. A graduate of the University of Western Ontario, Dr. Dost earned her medical...